Fennec Pharmaceuticals Inc. (FENC) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Fennec Pharmaceuticals Inc. (FENC) closed at USD 10.35 on 2026-10-15, a change of +22.2 % over the past year, with a market capitalization of USD 349.97M.

Fennec Pharmaceuticals Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Fennec Pharmaceuticals Inc. key figures

Previous close

USD 10.35 (2026-10-15)

1-year change

+22.2 %

Market cap

USD 349.97M

Enterprise value

USD 308.72M

P/E ratio (trailing)

-83.17

P/E ratio (forward)

10.53

EPS (trailing)

-0.12

EPS (forward)

0.95

PEG ratio

1.47

Price to book

8.24

Revenue growth

85.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.45

Employees

35

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Fennec Pharmaceuticals Inc. and compare it with other stocks.